Cybin net loss widens to $47.8 million in FY27 Q1 - CYBN News | RalliesCybin net loss widens to $47.8 million in FY27 Q1
C
CYBN• Trial spending and outlook
- Higher spending was driven by continued advancement of the APPROACH, EMBRACE, and EXTEND HLP003 Phase 3 trials.
- Cybin reiterated expectations for HLP003 Phase 3 topline data in Q4 2026, with HLP004 study design targeted for completion by end-Q3 2026.
Quarterly results and cash position
- Cybin posted a net loss of $47.8 million for the quarter ended June 30, 2026, widening from $24.6 million a year earlier.
- Cash-based operating expenses rose to $37.5 million from $23.9 million, while operating cash outflow increased to $37.1 million from $29.5 million.
- Cash totaled $166.4 million at June 30, 2026.
BENF
•
